A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Stopped Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.

Conditions

• EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Interventions

• DRUG: ASP8273 Capsules
• DRUG: ASP8273 Capsules A

Sponsor

Astellas Pharma Inc